A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China

• Published in: Advances in therapy Vol. 41; no. 11; pp. 4191 - 4204
• Main Authors: Zhang, Fengkui, Shen, Aizong, Ahmed, Waqas, Pollock, Richard F.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01-11-2024
• Subjects: Adult; Anemia, Iron-Deficiency - drug therapy; Cardiology; China - epidemiology; Cost-Benefit Analysis; Endocrinology; Female; Ferric Compounds - administration & dosage; Ferric Compounds - economics; Ferric Compounds - therapeutic use; Humans; Hypophosphatemia - chemically induced; Internal Medicine; Male; Maltose - administration & dosage; Maltose - analogs & derivatives; Maltose - economics; Maltose - therapeutic use; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Research; Pharmacology/Toxicology; Quality of Life; Quality-Adjusted Life Years; Rheumatology; China; Cost–utility; Ferric carboxymaltose; China; Iron deficiency anemia; Ferric derisomaltose
• ISSN: 0741-238X; 1865-8652; 1865-8652
• DOI: 10.1007/s12325-024-02987-7

Introduction
Intravenous (IV) iron is the recommended treatment for patients with iron deficiency anemia (IDA) unresponsive to oral iron treatment, in whom oral iron is contraindicated, or where rapid iron replenishment is required. Ferric derisomaltose (FDI) and ferric carboxymaltose (FCM) are high-dose, rapid-infusion, IV iron formulations that have recently been compared in three head-to-head randomized controlled trials (RCTs), which showed significantly higher incidence of hypophosphatemia after administration of FCM than FDI. The present study objective was to evaluate the cost–utility of FDI versus FCM in a population of patients with IDA in China.
Methods
A previously-published patient-level simulation model was used to model the cost–utility of FDI versus FCM in China. The number of infusions of FDI and FCM was modeled based on the approved posology of the respective formulations using simplified tables of iron need in a population of patients with body weight and hemoglobin levels informed by a Chinese RCT of FCM. Data on the incidence of hypophosphatemia was obtained from the PHOSPHARE-IDA RCT, while data on disease-related quality of life were obtained from SF-36v2 data from the PHOSPHARE-IBD RCT.
Results
Over the 5-year time horizon, patients received 3.98 courses of iron treatment on average, requiring 0.90 fewer infusions of FDI than FCM (7.69 vs. 6.79). This resulted in iron procurement and administration cost savings of renminbi (RMB) 206 with FDI (RMB 3,519 vs. RMB 3,312). Reduced incidence of hypophosphatemia-related fatigue resulted in an increase of 0.07 quality-adjusted life years and further cost savings of RMB 782 over 5 years, driven by reduced need for phosphate testing and replenishment. FDI was therefore the dominant intervention.
Conclusions
The results showed that FDI would improve patient quality of life and reduce direct healthcare expenditure versus FCM in patients with IDA in China.